2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.76

PP01.76 - Aaron Tan

Pdf Summary

The study explores the real-world outcomes and treatment patterns of extensive-stage small cell lung cancer (ES-SCLC) patients in Singapore. While immunotherapy has significantly impacted ES-SCLC treatment, translating trial results to real-world scenarios remains challenging. The research was conducted by experts from the National Cancer Centre Singapore and Duke-NUS Medical School, including Aaron C. Tan and colleagues.<br /><br />Key findings highlight that despite the introduction of immunotherapy, significant improvements in progression-free survival (PFS) and overall survival (OS) for ES-SCLC patients are limited. Many patients do not progress beyond first-line or second-line treatments, indicating a substantial unmet need for this cohort.<br /><br />The study includes patient data from the National Lung Cancer Research (NLCR) study in Singapore, encompassing 470 patients between 2003-2022—split into pre-immunotherapy (2015-2018) and post-immunotherapy (2019-2022) groups. Baseline demographics and characteristics reveal age ranges primarily between 66-69 years, predominantly males, with a high percentage of current or ex-smokers, and majorly of Chinese ethnicity. Most patients were diagnosed at the extensive stage, and a significant portion experienced brain metastases.<br /><br />The research underscores that while the first-line anti-PD-L1 inhibitor introduced post-2019 offers some hope, real-world effectiveness shows modest gains. Selection of post-first-line therapies includes platinum-etoposide rechallenge, taxanes, lurbinectedin, irinotecan, and temozolomide treatments, pointing to diverse treatment pathways but with limited advancements in patient outcomes. Overall, this investigation highlights an urgent need for more effective therapeutic strategies for ES-SCLC patients in real-world settings.

Keywords

extensive-stage small cell lung cancer

ES-SCLC

immunotherapy

real-world outcomes

progression-free survival

overall survival

National Cancer Centre Singapore

Duke-NUS Medical School

treatment patterns

therapeutic strategies